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ABSTRACT
Antithymocyte globulin (ATG) as part of conditioning regimens is known to reduce the incidence and severity of
acute and chronic graft-versus-host disease (aGVHD, cGVHD). The influence of ATG on transplant-related
mortality (TRM) and disease-free survival (DFS) is controversial, and may depend on the dose and timing of
ATG. We retrospectively compared 2 doses of ATG-Fresenius (ATG-F) in patients undergoing matched unre-
lated donor allogeneic hematopoetic stem cell transplantation (HSCT) for hematologic malignancies. A dose of
60 mg/kg body weight has previously been recommended for ATG-F. All patients received cyclosporine A and
short course methotrexate. ATG-F was administered at a dose of 30mg/kg on day –1 (ATG-30 group, n5 34) or
20mg/kg/day on days –3 to –1 (ATG-60 group, n5 49). There was no difference in time to leukocyte and platelet
engraftment in the 2 groups. The incidence of aGVHD grade II-IV (50% versus 53%, P5 .83) and grade III-IV
(27 versus 20%, P 5 .60) was similar in the ATG-30 versus ATG-60 groups, respectively. There was a trend to
a higher incidence of cGVHD in the ATG-30 group (59% versus 40%, P5 .14). The estimated 3-year incidence
of relapse was similar in the ATG-30 and ATG-60 groups (15% versus 16%, P 5 .84) whereas the 2-year TRM
was lower for the ATG-30 group (12% versus 33%, P 5 0.02), mainly because of a higher incidence of fatal in-
fections in the ATG-60 group. This resulted in a better DFS (73% versus 51%, P5 .07) for the ATG-30 group.
ATG-F (30 mg/kg) administered as a single dose on day –1 may lead to better outcome in patients undergoing
unrelated donor allogeneic HSCT compared to 60 mg/kg given in 3 equivalent doses. A prospective randomized
study comparing these 2 doses of ATG-F is warranted.
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Allogeneic hematopoetic stem cell transplantation
(HSCT) has over the past decades become the treat-
ment of choice for many hematologic malignant and
nonmalignant diseases [1,2]. Although better estab-
lished [3,4], transplantion from an HLA-identical
sibling is only available for about 1/3 of patients. The
use of stem cell grafts from matched unrelated donors
is associated with higher risk of complications and
lower survival rates compared to matched sibling do-
nors [5-9] for reasons that may include undetected
HLA disparities [10,11]. One of the key complications
of unrelated donor transplantation is graft-versus-host
disease (GVHD) [5-11]. Several strategies have beendeveloped to prevent severe GVHD, including ex
vivo T cell depletion [12,13], in vivo T cell depletion
with antithymocyte globulin (ATG) [14-17], or
alemtuzumab [18], as well as the use of posttransplant
combined ciclosporine A or FK506-based immuno-
suppression [19].
Inclusion of ATG in conditioning regimens for al-
logeneic stem cell transplantation (SCT) is associated
with reduced risk of acute and chronic GVHD
(aGVHD, cGVHD) and may also improve overall sur-
vival (OS) rates [20]. Presently there are 3 commercially
available ATG products: ATGAM (Pharmacia,
Piscataway, NJ) is produced by immunizing horses
with human thymocytes. Thymoglobulin (Genzyme,913
914 F. Ayuk et al.Cambridge, MA) is produced by immunizing rabbits
with human thymocytes, whereas ATG-Fresenius
(ATG-F, Fresenius, Germany) is produced by immu-
nizing rabbits with the jurkat cell line. ATG is usually
administered on the days preceeding stem cell infusion
in single or multiple doses. The different ATG prepa-
rations listed above possess differential immunomodu-
latory potencies and are thus used in different doses.
For a given ATG preparation the observed effect may
not only be dependent on the dose applied but also
on timing of the application [21]. ATG administered
prior to transplantation can still be detected in patients
in the days after transplantation [22]. The mechanism
of immunosuppresion induced by ATG may depend
on the concentration attained in vivo and includes T
cell depletion, modulation of adhesion and trafficking
molecules, depletion andmodulation of dendritic cells,
as well as induction of regulatoryT cells [23]. Although
very lowdosesmay lose the immunosuppressive effects,
very high doses of ATG may aggravate the delay in
immune recovery and increase the risk of infections
[24-27]. The recommended dose for Thymoglobulin
is 6-8 mg/kg body weight (BW) [24]. For ATG-F, a to-
tal dose of 60 mg/kg BW is recommended [28]. It is
important to note that the recommended doses of
ATGare based on a few studies; thus, further investiga-
tion is required to established optimal dosing and tim-
ing. In the present studywe compare 2 doses of ATG-F
(30 mg/kg versus 60 mg/kg BW) administered as part
of conditioning regimen for allogeneic SCT from
matched unrelated donors.
PATIENTS AND METHODS
Between July 1997 and October 2005, 83 adult and
pediatric patients with hematologic malignancies were
treated with bone marrow or blood stem cell grafts
fromanunrelated donor.GVHDprophylaxis consisted
of ATG,methotrexate, and cyclosporine A. The condi-
tioning regimen consisted of total-body irradiation
(TBI) and alkylating agents or a combined alkylating
therapy. Patients’ characteristics are listed in Table 1.
Patients with CML in first chronic phase, AML in
first or second complete remission, ALL in first or sec-
ond complete remission, and MDS (RA and RARS)
were classified as ‘‘good-risk’’ patients. All other pa-
tients were classified as ‘‘bad risk.’’ Follow-up only
includes surviving patients.
Donor Selection and HLATyping
HLA-A and HLA-B antigen loci were typed using
the reverse SSO line-blot assay. HLA-DRB1 and
HLA-DQB1 loci were typed using the reverse SSO
dotblot method. Helmberg-Score software was used
for allelic assignment in conjunction with the most
recent nomenclature report and library [29-31].
Remaining ambiguities were resolved by sequencingof amplimers obtained after SSP with appropriate
primers. HLA-A and B were resolved at the 2-digit
level, whereas HLA-DRB1 and DQB1 were typed to
the 4-digit allelic level. Typing for HLA-C was not
routinely performed and disparities, if observed, were
not considered as mismatch.
Conditioning Regimens
Patients with CML received busulfan (14–16 mg/
kg BW orally) and cyclophosphamide (2  60 mg/
kg/BW) or TBI (12 Gy, divided into 2 Gy fractions
twice daily) and cyclophosphamide (2  60 mg/kg/
BW). Patients with AML and MDS received busulfan
Table 1. Patients’ and Donors’ Characteristics
Characteristic
ATG-30
n 5 34
ATG-60
n 5 49
P-
Value
Patient age .30
Median 37 (r: 1-61) 35 (r: 1-52)
Donor age .79
Median 36 (r: 21-51) 33 (r: 21-58)
Patient sex .4
Male 14 (41%) 26 (53%)
Female 20 (59%) 23 (47%)
Donor sex .02
Male 17 (50%) 37 (75%)
Female 17 (50%) 12 (25%)
Donor/patient sex
match
.5
Sex matched 19 (56%) 32 (65%)
Sex mismatched 15 (44%) 17 (35%)
Graft source .7
Bone marrow 14 (41%) 17 (35%)
PBSC 20 (59%) 32 (65%)
Diagnosis .005
CML 7 (21%) 15 (31%)
ALL 7 (21%) 20 (41%)
AML, sAML 17 (50%) 7 (14%)
MDS, sMDS, CMML 3 (8%) 7 (14%)
Risk .63
Good risk 22 (65%) 35 (71%)
Bad risk 12 (35%) 14 (29%)
Transplant period .82
1997-2002 14 (41%) 18 (37%)
2003-2005 20 (59%) 31 (63%)
CMV (patient) .8
Seropositive 15 (44%) 23 (47%)
Seronegative 19 (56%) 26 (53%)
CMV (donor) .08
Seropositive 11 (32%) 26 (53%)
Seronegative 23 (68%) 23 (47%)
CD 341 cells x 106/kg .84
Median 5.9 (r: 1.2-16.8) 5.8 (r: 0.8-27.7)
Conditioning (Busulfan
versus TBI)
.3
Busulfan 24 (71%) 28 (57%)
TBI 10 (29%) 21 (43%)
Conditioning with
Etoposide
23 (68%) 29 (59%) .5
TBI indicates total-body irridation; ATG, antithymocyte globulin;
CMV, cytomegalovirus; AML, acute myelogenous leukemia;
ALL, acute lymphoblastic leukemia; MDS, myelodysplastic syn-
dromes; PBSC, peripheral blood progenitor cells.
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cyclophosphamide (2  60 mg/kg/BW). Patients with
ALL received TBI (12 Gy, divided into 2 Gy fractions
twice daily), cyclophosphamide (2  60 mg/kg/BW),
and etoposide (45mg/kg BW). Conditioning regimens
were balanced in the 2 groups.
GVHD Prophylaxis and Management
All patients received cyclosporine A (3 mg/kg i.v.),
starting on day 21 and additional short-course meth-
otrexate (10mg/m2) on days 1, 3, and 6 after transplan-
tation. ATG-F was administered at a dose of 30 mg/kg
on day –1 (ATG-30 group) or 20 mg/kg/day on days –
3 to –1 (ATG-60 group). Initially (1997) all patients re-
ceived 30 mg/kg of ATG-F. Because of the notion at
that time that higher doses may be of advantage, we in-
creased the dose of ATG and eventually adopted the
proposed standard dose of 60 mg/kg. In an interima-
nalysis we noticed that the ATG-30 group had been
doing very well so we reintroduced this lower dose of
ATG in 2002. Acute GVHD was treated with methyl-
prednisolone (2 mg/kg). Second-line treatment in-
cluded tacrolimus (instead of cyclosporine A),
mycophenolat mophetil and basiliximab.
Grading of GVHD
The grading of aGVHD was performed according
to standard criteria. The grades were assigned on the
severity of aGVHD of the skin, liver, and gastrointes-
tinal tract [32]. Chronic GVHD was evaluated in
patients alive beyond day 180 posttransplant and
characterized as ‘‘limited’’ or ‘‘extensive’’ [33].
Supportive Care
All patients were nursed in reverse isolation in
a conventional or laminar air flow room. Acyclovir
and fluconazol or itraconazol were routinely admi-
nisted to all patients. Prophylaxis against Pneumocystis
carinii consisted of cotrimoxazole or pentamidine in-
halation. All blood products were irradiated with 25
Gy. CMV-negative patients received only CMV-
negative blood products. CMV-positive patients
were monitored at least weekly for CMV infection
by PCR and/or antigenaemia assay. Preemptive ther-
apy was started with 10 mg/kg gancyclovir per day
after 2 consecutive positive PCR results or 1 positive
antigenaemia assay. Neutropenic fever was treated
with broad-spectrum antibiotics.
Statistical Considerations
All analyses were performed with the SPSS version
10/11 (SPSS Inc., Chicago, IL). Endpoints of the anal-
ysis were transplant-related mortality (TRM), inci-
dence, and severity of aGVHD, incidence and
severity of cGVHD, incidence of relapse, disease-
free survival (DFS) and OS. TRM is defined as fromany cause other than recurrent malignancy. DFS refers
to patients alive without relapse.
The probability of OS and DEF were calculated
using the method of Kaplan-Meier. Comparison of
groups was performed using the log-rank test. Cumu-
lative incidence of TRM and relapse were calculated
using a Gray-test [34] (according to NHMRCClinical
Trials Centre, University of Sydney, 2007, Prof. Val
Gebski), taking into account competing risks TRM
and relapse. The following factors were included in
the analysis (only pretransplant parameters): patients’
age, donors’ age, patients’ sex, donors’ sex, diagnosis,
good-risk versus bad-risk disease, CMV status of pa-
tient, CMV status of donor, stem cell source (bone
marrow versus peripheral blood stem cells), TBI versus
busulfan-based conditioning, etoposide versus none-
toposide conditioning, number of transplanted
CD341 cells/kg BW, sex mismatch versus matched,
period of transplant (1997-2002 versus 2003-2005),
and ATG dose. Variables for which a P-value \.1
was found were then entered into a multivariate Cox
regression model.
RESULTS
Engraftment
One patient in the ATG-60 group died before en-
graftment. In all, no graft failure was observed. There
was no difference in time to leukocyte engraftment for
the ATG-30 (15 days) and ATG-60 (16 days) groups,
P 5 .16. Time to platelet engraftment was 20 days in
both groups, P 5 .85 (Table 2).
GVHD
All 83 patients were evaluable for aGVHD,
whereas 67 patients were evaluable for cGVHD. The
incidence of aGVHD grade II-IV (50% versus 53%,
P 5 .83) and grade III-IV (27 versus 20%, P 5 .60)
was similar in the ATG-30 versus ATG-60 groups,
respectively. There was a trend to a higher incidence
of cGVHD in the ATG-30 group (59 versus 40 %,
P 5 .14).
Infections and Other Causes of Death
Overall, 9 patients in the ATG-30 group and 21
patients in the ATG-60 group died. Thirteen of 21
(62%) deaths in the ATG-60 and 3 of the 9 deaths
(33%) in the ATG-30 group were associated with in-
fections with or without GVHD (Table 3). Routine
monitoring for viraemia was performed for CMV.
No cases of EBV-associated posttransplant lympho-
proliferative disorders were observed. The incidence
of CMV reactivation was similar in the ATG-30 and
ATG-60 groups (27% versus 26%). Four of 21 deaths
(19%) in the ATG-60 group and 1 of 9 (11%) in the
ATG-30 group were associated with viral infections.
Eight deaths (38%) in the ATG-60 group and 2
916 F. Ayuk et al.Table 2. Clinical Outcomes According to ATG Dose
ATG-30 n 5 34 ATG-60 n 5 49 P-Value
Graft-failure 0/34 (0%) 0/48 (0%) 1.0
Engraftment (day) median (range)
Leukocytes $1.0  109/L 15 (11-28) 16 (9-28) .16
Platelets $20  109/L 20 (10-60) 20 (10-130) .85
Acute GVHD
Grade II-IV 17/34 (50%) 26/49 (53%) .83
Grade III-IV 9/34 (27%) 10/49 (20%) .60
Chronic GVHD
Overall 17/29 (59%) 15/38 (40%) .14
Limited 10/29 (35%) 8/38 (21%)
Extensive 7/29 (24%) 7/38 (19%)
TRM (at 2 years)* 12% (95% CI:1%-23%) 33% (95% CI: 20%-46%) .02
Relapse (at 3 years)* 15% (95% CI: 3%-27%) 16% (95% CI: 5%-27%) .84
OS (at 3 years)† 72% (95%CI: 57%-87%) 56% (95%CI: 42%-70%) .12
DFS (at 5 years)† 73% (95%CI:62%-88%) 51% (95%CI:36%-66%) .07
Follow-up, median days (range) 658 (188-3114) 850 (192-1389) .90
OS indicates overall survival; DFS, disease-free survival; TRM, transplant-related mortality, ATG, antithymocyte globulin; GVHD, graft-
versus-host disease.
*Gray-test.
†Log-rank test.(22%) in the ATG-30 group were associated with fun-
gal infections. Five deaths (24%) in the ATG-60 group
and 5 (56%) in the ATG-30 group were because of
relapse.
OS
The estimated 3-year OS was 72% for patients
in the ATG-30 group and 56% for those in the
ATG-60 group, P 5 .12 (Figure 1). None of the rele-
vant parameters had significant influence on OS in the
univariate analysis.
DFS
There was a trend to better estimated 3-year DFS
for the ATG-30 group with 73% compared to 51% for
the ATG-60 group, P 5 .07 (Figure 2). In the univar-
iate analysis, ATG dose 60 mg/kg (relative risk [RR]:
2.02, P 5 .08) and patient’s CMV-seropositivity (RR:
1.97, P 5 .06) had negative impact on outcome. In
the multivariate analysis, both ATG dose of 60 mg/
kg (RR: 1.9, P5 .09) and patient’s CMV-seropositivity
(RR: 1.9, P 5 .09) retained their negative impact on
DFS (Table 4.).
Table 3. Causes of Death According to ATG Dose
Cause of death ATG-30 ATG-60
Infection 1 GVHD 1 (11.1%) 5 (23.8%)
Infection 2 (22.2%) 8 (38.1%)
Relapse 5 (55.6%) 5 (23.8%)
Toxicity 1 (11.1%) 2 (9.5%)
Others 0 (0%) 1 (4.8%)
Total 9 (100%) 21 (100%)
ATG indicates antithymocyte globulin; GVHD, graft-versus-host
disease.Treatment-Related Mortality
The 2-year cumulative incidence of treatment-re-
lated mortality (using the Gray-test for competing
risks) was lower for the ATG-30 group (12%) com-
pared to the ATG-60 group (33%), P5 .02 (Figure 3).
In the univariate analysis period of transplant 2002-
2005 was also associated with lower treatment-related
mortality (p 5 .08). In the multivariate analysis, both
ATG dose 60 mg/kg (RR: 3.5, P5 .03) and transplant
period 1997-2002 (RR: 2.5, P 5 .045) retained their
negative influence on treatment-related mortality.
Relapse
The 3-year cumulative incidence of relapse (using
Gray-test for competing risks) was similar in the
ATG-30 and ATG-60 groups (15% versus 16%), P 5
.84 (Figure 4). Bad-risk disease (RR: 4.0, P 5 .046)
was the only factor with significant impact on relapse.
Conditioningwithetoposidewas associatedwitha trend
to higher relapse incidence in the univariate analysis
Table 4. Multivariate Proportional Hazard Regression Analysis of All
Patients
Relative
Risk
Confidence
Interval (95 % CI)
P-
Value
DFS
ATG dose 60 mg/kg 1.9 0.90-4.21 .09
Patient CMV-seropositive 1.9 0.94-3.86 .08
TRM
ATG dose 60 mg/kg 3.5 1.03-9.30 .03
Transplant year 1997-2002 2.5 1.02-6.00 .045
DFS indicates disease-free survival; TRM, transplant-related mor-
tality; ATG, antithymocyte globulin; CMV, cytomegalovirus.
Two Doses of Antithymocyte Globulin in Allogeneic Stem Cell Transplantation 917(P5 .07). However, it must be taken into consideration
that all patientswithALLandAMLbut only 29%of pa-
tientswithCMLreceived etoposide.This is of relevance
because the 3-year relapse rates for patients with ALL,
AML, andCMLwere 29%, 25%, and 9%, respectively.
DISCUSSION
The dose and timing of ATG may have significant
impact on outcome of patients undergoing allogeneic
SCT from unrelated donors.
The positive impact of ATG on the incidence of
aGVHD and cGVHD is well documented [20]; how-
ever, the effects on treatment-related mortalizy and
DFS remain controversial [14-17,35] and may depend
on the dose and timing as well as on the brand of ATG
used. For Thymoglobulin, doses between 4.5 and 8
mg/kg BW have been recommended, depending on
timing [17,24,36].
A retrospective analysis in CML patients undergo-
ing matched unrelated donor allografting reported
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Figure 1. Represents Kaplan-Meier estimates of OS.
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Figure 2. Represents Kaplan-Meier estimates and DFS, respec-
tively.better OS and DFS for patients receiving $60 mg/kg
BW of ATG-F compared to \60 mg/kg BW. This
was in part because of a higher incidence of severe
acute GVHD in the group with\60 mg/kg ATG-F
[28]. Based on these results, ATG-F at a dose of 60
mg/kg or higher has was recommended for matched
unrelated donor SCT [20,28]. In the above study
ATG was given in 4 equivalent doses from days –5 to
–2 or 3 equivalent dosis from days –3 to – 1. It must
be noted that of the 31 patients who received ATG
\60 mg/kg, 18 (58%) received 20 mg/kg and 11
(35.5%) received 40 mg/kg in 3 or 4 equivalent doses.
This split dosing of a relatively low dose of ATG may
have led to the poor outcome.
In our study, we report better outcome for patients
who received 30 mg/kg of ATG-F as a single applica-
tion on day –1 compared to those receiving 60 mg/kg
administered in 3 equivalent doses from day –3 to –1.
For the subgroup of patients with CML (n 5 22), our
data including patients in both ATG-dose groups are
Figure 3. Represents cumulative estimates of TRM using the Gray-
test for competing risks.
Figure 4. Represents relapse rates obtained using the Gray-test for
competing risks.
918 F. Ayuk et al.comparable with those of the above study with respect
to OS (62% versus 66%) and DFS (57% versus 56%).
In our study the incidence and severity of aGVHD
was similar in the ATG-30 and ATG-60 group. How-
ever, there was a trend to increased incidence and se-
verity of cGVHD in patients who received ATG 30
mg/kg (59 versus 40%, P 5 .14). There was no signif-
icant difference in the incidence of relapse between the
2 groups. Because more patients in the ATG-30 group
died of relapse, we performed analysis using the Gray-
test taking into consideration competing risks treat-
ment-relatedmortality and relapse. Treatment-related
mortality was higher in the ATG-60 group (12%
versus 33%, P5 .02), mainly because of a higher inci-
dence of fatal infections. Although we do not have data
comparing immune reconstitution in the 2 groups,
there is substantial evidence that higher doses of
ATG are associated with slower immune recovery
and a higher incidence of fatal infections [17,24-27].
The lower treatment-relatedmortality and compa-
rable relapse rate led to a trend to improvedDFS in the
ATG-30 group (73% versus 51%, P 5 .07).
Our results indicate that 30 mg/kg of ATG-F
administered as a single dose on day –1 may lead to
a better outcome in patients undergoing unrelated do-
nor allogeneic HSCT compared to 60 mg/kg given in
3 equivalent doses. These data are in contrast to the
previous report recommending a dose of $60 mg/kg.
A prospective randomized study comparing these 2
doses of ATG-Fwith the discussed timing is warranted
and underway.
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